| Genmab A/S |
| Fecha/Hora | / |
| Dif. / Dif.(%) | - / |
| Bid | - |
| Ask | - |
| Apertura | - |
| Cierre del día anterior | - |
| Máxima sesión | - |
| Mínima sesión | - |
| Volumen [DKK] | - |
| Volumen [Unidades] | |
| Fijación de precios | |
| ISIN | DK0010272202 |
| Símbolo | GMAB |
| Bolsa | OMX Nordic |
| Tipo | Acciones |
Otras Bolsas
| Bolsa | Último | Volumen | |
|---|---|---|---|
| OMX Nordic | 2.102,00 |  |
172.254 |
| Cboe Europe .. | 2.102,00 | |
28.882 |
| Turquoise | 2.103,50 | |
12.082 |
| London Inter.. | 2.101,5 | |
6.746 |
| Cboe Europe .. | 2.103,50 | |
543 |
| Cboe Europe .. | 2.102,50 | |
267 |
| TradeGate | 282,200 | |
178 |
| Nasdaq Other.. | 338,9200 | |
107 |
| Frankfurt | 283,2000 |  |
45 |
| Stuttgart | 283,700 | |
24 |
| gettex | 284,700 | |
4 |
| Vienna Globa.. | 282,90 | |
0 |
| München | 286,00 | |
0 |
| Düsseldorf | 281,50 | |
0 |
| Berlin | 282,40 | |
0 |
| Lang & Schwa.. | 281,60 | |
|
| Mexico | 7.638,15 | |
11.330 |
Noticias
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
09.04.2021 / 22:00 - GlobeNewswire - Pfizer and BioNTech Confirm High Efficacy and No Serious Safety Concerns Through Up to Six Months Following Second Dose in Updated Topline Analysis of Landmark COVID-19 Vaccine Study
01.04.2021 / 12:45 - GlobeNewswire - Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents
31.03.2021 / 12:45 - GlobeNewswire - BioNTech Announces Full Year 2020 Financial Results and Corporate Update
30.03.2021 / 12:30 - GlobeNewswire - Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
30.03.2021 / 07:21 - GlobeNewswire
Tiempo real